141 related articles for article (PubMed ID: 31115855)
1. Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease.
Bongers PJ; Kluijfhout WP; Verzijl R; Lustgarten M; Vermeer M; Goldstein DP; Devon K; Rotstein LE; Asa SL; Brierley JD; Tsang RW; Ezzat S; Vriens MR; Mete O; Pasternak JD
Ann Surg Oncol; 2019 Aug; 26(8):2533-2539. PubMed ID: 31115855
[TBL] [Abstract][Full Text] [Related]
2. Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management.
Poma AM; Viola D; Macerola E; Proietti A; Molinaro E; De Vietro D; Elisei R; Materazzi G; Miccoli P; Basolo F; Ugolini C
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4109-e4117. PubMed ID: 34061965
[TBL] [Abstract][Full Text] [Related]
3. Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma.
Beninato T; Scognamiglio T; Kleiman DA; Uccelli A; Vaca D; Fahey TJ; Zarnegar R
Surgery; 2013 Dec; 154(6):1331-6; discussion 1336. PubMed ID: 24238051
[TBL] [Abstract][Full Text] [Related]
4. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.
Carr AA; Yen TWF; Ortiz DI; Hunt BC; Fareau G; Massey BL; Campbell BH; Doffek KL; Evans DB; Wang TS
Thyroid; 2018 Nov; 28(11):1462-1467. PubMed ID: 30215297
[TBL] [Abstract][Full Text] [Related]
5. Tall cell variant of papillary thyroid carcinoma: a population-based study in Iceland.
Axelsson TA; Hrafnkelsson J; Olafsdottir EJ; Jonasson JG
Thyroid; 2015 Feb; 25(2):216-20. PubMed ID: 25322334
[TBL] [Abstract][Full Text] [Related]
6. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Song E; Jeon MJ; Oh HS; Han M; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Song DE; Kim WG
Eur J Endocrinol; 2018 Sep; 179(3):135-142. PubMed ID: 29875289
[TBL] [Abstract][Full Text] [Related]
7. A Critical Assessment of Diagnostic Criteria for the Tall Cell Subtype of Papillary Thyroid Carcinoma-How Much? How Tall? And When Is It Relevant?
Turchini J; Fuchs TL; Chou A; Sioson L; Clarkson A; Sheen A; Delbridge L; Glover A; Sywak M; Sidhu S; Gill AJ
Endocr Pathol; 2023 Dec; 34(4):461-470. PubMed ID: 37864666
[TBL] [Abstract][Full Text] [Related]
8. Assessment of risk factors in metastatic/recurrent tall cell variant of papillary thyroid carcinoma.
Okuyucu K; Alagoz E; Ince S; Arslan N
Endokrynol Pol; 2017; 68(6):623-630. PubMed ID: 29022644
[TBL] [Abstract][Full Text] [Related]
9. Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study.
Chereau N; Giudicelli X; Pattou F; Lifante JC; Triponez F; Mirallié E; Goudet P; Brunaud L; Trésallet C; Tissier F; Leenhardt L; du Montcel ST; Menegaux F
J Clin Endocrinol Metab; 2016 Dec; 101(12):4603-4610. PubMed ID: 27626975
[TBL] [Abstract][Full Text] [Related]
10. Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods.
Russo M; Malandrino P; Moleti M; Vermiglio F; Violi MA; Marturano I; Minaldi E; Vigneri R; Pellegriti G; Regalbuto C
J Endocrinol Invest; 2017 Nov; 40(11):1235-1241. PubMed ID: 28528434
[TBL] [Abstract][Full Text] [Related]
11. Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.
Wong KS; Higgins SE; Marqusee E; Nehs MA; Angell T; Barletta JA
Endocr Pathol; 2019 Mar; 30(1):43-48. PubMed ID: 30565013
[TBL] [Abstract][Full Text] [Related]
12. Impact of tall cell variant histology on predicting relapse and changing the management of papillary thyroid carcinoma patients.
Gunalp B; Okuyucu K; Ince S; Ayan A; Alagoz E
Hell J Nucl Med; 2017; 20(2):122-127. PubMed ID: 28697188
[TBL] [Abstract][Full Text] [Related]
13. Tall Cell Variant Papillary Thyroid Carcinoma in Saudi Patients: A clinicopathological and Outcomes Analysis.
Al-Qahtani KH; Tunio MA; Al Asiri M; Bayoumi Y; Alshehri WA; Aljohani NJ; Ali AA; Fatani H
Saudi Med J; 2016 Nov; 37(11):1220-1224. PubMed ID: 27761560
[TBL] [Abstract][Full Text] [Related]
14. Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves' Disease.
Boutzios G; Vasileiadis I; Zapanti E; Charitoudis G; Karakostas E; Ieromonachou P; Karatzas T
Thyroid; 2014 Feb; 24(2):347-54. PubMed ID: 23786233
[TBL] [Abstract][Full Text] [Related]
15. Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer.
Beck AC; Rajan A; Landers S; Kelley S; Bellizzi AM; Lal G; Sugg SL; Howe JR; Chan CH; Weigel RJ
Surgery; 2022 Jan; 171(1):245-251. PubMed ID: 34362588
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of tall cells in papillary thyroid carcinoma: A case-control study.
Stenman S; Siironen P; Mustonen H; Lundin J; Haglund C; Arola J
Tumour Biol; 2018 Jul; 40(7):1010428318787720. PubMed ID: 30010512
[TBL] [Abstract][Full Text] [Related]
18. Pathologic study and clinical significance of Hürthle cell papillary thyroid carcinoma.
Mai KT; Thomas J; Yazdi HM; Commons AS; Lamba M; Stinson AW
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):329-37. PubMed ID: 15536332
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
Wang F; Yu X; Shen X; Zhu G; Huang Y; Liu R; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Wang Y; Liu S; Zhao J; Zhao S; Xing M
J Clin Endocrinol Metab; 2017 Sep; 102(9):3241-3250. PubMed ID: 28582521
[TBL] [Abstract][Full Text] [Related]
20. Lobectomy Is Feasible for 1-4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence.
Song E; Han M; Oh HS; Kim WW; Jeon MJ; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Hong SJ; Sung TY; Kim WG
Thyroid; 2019 Jan; 29(1):64-70. PubMed ID: 30375260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
